context
respiratori
diseas
chronic
obstruct
pulmonari
diseas
copd
lead
caus
mortal
worldwid
despit
much
develop
area
drug
develop
current
effect
medicin
avail
treatment
diseas
imbal
proteas
antiproteas
ratio
copd
lung
remain
import
aspect
copd
pathophysiolog
sever
studi
shown
efficaci
antiproteas
therapi
vitro
vivo
copd
model
howev
indepth
studi
requir
valid
efficaci
lead
drug
molecul
target
proteas
review
discuss
current
statu
proteasedirect
drug
use
treat
copd
explor
futur
prospect
util
potenti
antiproteasebas
therapeut
treatment
diseas
viral
pathogen
may
also
play
major
role
develop
copd
contribut
rise
exacerb
frequenc
among
copd
popul
given
increas
healthcar
societ
burden
associ
increas
copd
number
therapeut
programm
ongo
develop
strategi
treatment
copd
beyond
scope
review
discuss
ongo
therapeut
programm
focu
current
statu
antiproteas
therapi
copd
proteas
antiproteas
imbal
consid
one
core
physiolog
mechan
involv
pathogenesi
copd
one
major
genet
caus
copd
defici
serin
proteas
inhibitor
regul
neutrophil
chemotaxi
involv
signal
addit
also
shown
regul
level
cathepsin
b
defici
patient
treat
augment
therapi
four
differ
type
proteas
name
serin
cystein
aspart
mmp
thought
involv
pathogenesi
copd
among
serin
proteas
specif
neutrophil
elastas
ne
dipeptidyl
peptidas
cathepsin
g
proteinas
cathepsin
c
mast
cellderiv
tryptas
chymas
found
associ
sever
copd
metalactiv
proteinas
includ
found
highli
express
vivo
model
clinic
sampl
cystein
proteas
includ
cathepsin
k
cathepsin
also
shown
upregul
copd
patient
final
elev
level
aspart
proteas
cathepsin
cathepsin
e
demonstr
copd
patient
tissu
variou
copd
model
neutrophil
elastas
ne
chronic
obstruct
pulmonari
diseas
copd
consid
one
major
diseas
modern
time
continu
rise
pollut
across
globe
combin
continu
cigarett
smoke
develop
develop
countri
copd
set
becom
third
lead
caus
death
despit
major
effort
find
treatment
copd
effect
therapeut
strategi
remain
elus
copd
progress
lower
respiratori
tract
disord
encompass
chronic
bronchiti
emphysema
chronic
bronchiti
caus
increas
secret
mucu
differenti
goblet
cell
lead
thicker
mucu
layer
line
airway
emphysema
caus
destruct
termin
bronchiol
lead
decreas
ga
exchang
lower
airway
diseas
result
decreas
pulmonari
function
qualiti
life
cigarett
smoke
consid
primari
caus
copd
although
smoker
thought
develop
copd
fact
ration
fact
around
copd
case
either
exsmok
current
smoker
moreov
around
copd
case
underli
genet
compon
caus
defici
serum
glycoprotein
antitrypsin
primari
serin
antiproteas
respons
protect
lung
action
neutrophilderiv
serin
proteas
copd
also
consid
agerel
disord
therefor
increas
worldwid
age
popul
number
patient
diagnos
copd
also
increas
present
bronchodil
mainstay
treatment
manag
copd
fall
short
overal
effect
addit
environment
insult
cigarett
smoke
bacteri
neutrophil
elastas
ne
primari
enzym
present
azurophil
granul
neutrophil
cytoplasm
thought
play
role
proteolyt
breakdown
phagocytos
molecul
neutrophil
first
cell
type
arriv
lung
follow
stimul
microbi
pathogen
smoke
variou
environment
exposur
howev
unoppos
ne
activ
lung
may
lead
lung
parenchyma
destruct
subsequ
increas
product
inflammatori
mediat
consid
primari
regul
ne
activ
normal
lung
account
around
antin
activ
lower
respiratori
tract
provid
protect
underli
connect
tissu
elev
serum
level
ne
found
associ
copd
sever
addit
higher
ne
concentr
exist
saliva
exhal
breath
condens
copd
patient
therefor
sever
previou
studi
focus
inhibit
ne
treatment
strategi
copd
first
ne
inhibitor
use
clinic
trial
copd
figur
cyclic
thiol
compound
deriv
homocystein
lacton
thiolact
acid
found
competit
revers
ne
inhibitor
oral
administr
dose
mg
twice
day
week
test
check
efficaci
reduc
level
lung
destruct
marker
studi
urinari
level
desmosin
plasma
elastinderiv
peptid
thought
deriv
ne
activ
measur
interestingli
found
effect
copd
patient
recent
diagnos
copd
less
establish
diseas
cyclic
peptid
lacton
isol
ferment
broth
streptomyc
resistomycificu
shown
effect
reduc
porcin
pancreat
elastas
ppe
induc
emphysema
hamster
figur
median
effect
dose
around
mgkg
bodi
weight
intratrach
instil
effect
inhibit
increas
observ
lung
complianc
vital
capac
lung
week
ppe
treatment
howev
despit
promis
studi
followup
studi
use
carri
found
effect
reduc
lung
hemorrhag
neutrophil
accumul
associ
neinduc
rat
emphysema
model
figur
oral
preadministr
dose
mgkg
found
reduc
increas
hemoglobin
concentr
well
neutrophil
count
myeloperoxidas
activ
bronchoalveolar
lavag
bal
fluid
within
h
human
ne
instil
addit
histopatholog
studi
demonstr
decreas
emphysemat
chang
treat
group
furthermor
shown
reduc
neinduc
increas
lung
complianc
mean
linear
intercept
l
rat
model
howev
despit
promis
result
later
shown
deleteri
effect
liver
function
rat
emphysema
model
figur
oral
preadministr
dose
mgkg
found
reduc
increas
hemoglobin
concentr
well
neutrophil
count
myeloperoxidas
activ
bronchoalveolar
lavag
bal
fluid
within
h
human
ne
instil
addit
histopatholog
studi
demonstr
decreas
emphysemat
chang
treat
group
furthermor
shown
reduc
neinduc
increas
lung
complianc
mean
linear
intercept
lm
rat
model
howev
despit
promis
result
later
shown
deleteri
effect
liver
function
anoth
studi
specif
ne
inhibitor
shown
profound
effect
acut
chronic
phase
emphysema
guinea
pig
model
figur
oral
administr
dose
rang
mgkg
result
lower
total
neutrophil
cell
count
bal
fluid
dosedepend
manner
moreov
lower
level
desmosin
hydroxyprolin
bal
fluid
addit
express
inflammatori
mediat
macrophag
inflammatori
protein
monocyt
chemoattract
protein
tumor
necrosi
also
found
reduc
upon
administr
importantli
also
found
effect
reduc
inflamm
chronic
smoke
expos
guinea
pig
interestingli
saccharid
deriv
found
potent
earlier
test
ne
inhibitor
oral
preadministr
dose
rang
mgkg
bodi
weight
elastas
instil
shown
effect
reduc
elastaseinduc
lung
hemorrhag
mice
also
shown
decreas
lung
hemorrhag
lung
injuri
anoth
studi
specif
ne
inhibitor
shown
profound
effect
acut
chronic
phase
emphysema
guinea
pig
model
figur
oral
administr
dose
rang
mgkg
result
lower
total
neutrophil
cell
count
bal
fluid
dosedepend
manner
moreov
lower
level
desmosin
hydroxyprolin
bal
fluid
addit
express
inflammatori
mediat
macrophag
inflammatori
protein
monocyt
chemoattract
protein
tumor
necrosi
also
found
reduc
upon
administr
importantli
also
found
effect
reduc
inflamm
chronic
smoke
expos
guinea
pig
interestingli
saccharid
deriv
found
potent
earlier
test
ne
inhibitor
oral
preadministr
dose
rang
mgkg
bodi
weight
elastas
instil
shown
effect
reduc
elastaseinduc
lung
hemorrhag
mice
also
shown
decreas
lung
hemorrhag
lung
injuri
preclin
studi
oral
avail
ne
inhibitor
found
effect
human
neand
cigarett
smokeinduc
emphysema
model
figur
affin
studi
shown
bind
ne
rapidli
compar
moreov
show
specif
ne
compar
ne
inhibitor
sivelestat
acut
ne
instil
model
shown
effect
reduc
bal
hemoglobin
level
dose
mgkg
bal
hydroxyprolin
desmosin
level
dose
mgkg
mgkg
respect
chronic
smokeinduc
emphysema
mous
model
shown
effect
reduc
bal
neutrophil
level
dose
mgkg
bal
level
dose
mgkg
bodi
weight
moreov
shown
complet
prevent
airspac
enlarg
emphysema
small
airway
remodel
chronic
model
although
shown
effect
preclin
model
shown
ineffect
clinic
trial
copd
random
placebocontrol
phase
iib
trial
three
month
treatment
improv
neither
lung
function
sign
symptom
associ
copd
patient
histori
budesonideformoterol
therapi
anoth
clinic
trial
copd
patient
dose
mg
twice
day
reduc
inflamm
lung
damag
appli
combin
tiotropium
addit
synthet
proteas
inhibitor
plantderiv
proteas
inhibitor
evalu
bauhinia
bauhinioid
l
plant
caesalpinioidea
subfamili
shown
secret
mani
proteas
inhibitor
among
bauhinia
bauhinioid
kallikrein
proteinas
inhibitor
rbbki
bauhinia
bauhinioid
scruzipain
inhibitor
bbci
found
effect
amelior
elastaseinduc
emphysema
figur
model
elastaseinduc
emphysema
model
rbbki
shown
effect
reduc
elastaseinduc
inflamm
extracellular
matrix
remodel
moreov
rbbki
reduc
number
bal
cell
inflammatori
marker
includ
lung
remodel
marker
oxid
stress
marker
eno
ino
marker
respiratori
airway
alveolar
wall
addit
rbbki
diminish
increas
lung
mechan
stress
paramet
respiratori
system
elast
respiratori
system
resist
airway
resist
lung
tissu
elast
lung
tissu
damp
bbci
also
shown
effect
amelior
lung
inflamm
extracellular
lung
remodel
dose
mgkg
preclin
studi
oral
avail
ne
inhibitor
found
effect
human
neand
cigarett
smokeinduc
emphysema
model
figur
affin
studi
shown
bind
ne
rapidli
compar
moreov
show
specif
ne
compar
ne
inhibitor
sivelestat
acut
ne
instil
model
shown
effect
reduc
bal
hemoglobin
level
dose
mgkg
bal
hydroxyprolin
desmosin
level
dose
mgkg
mgkg
respect
chronic
smokeinduc
emphysema
mous
model
shown
effect
reduc
bal
neutrophil
level
dose
mgkg
bal
level
dose
mgkg
bodi
weight
moreov
shown
complet
prevent
airspac
enlarg
emphysema
small
airway
remodel
chronic
model
although
shown
effect
preclin
model
shown
ineffect
clinic
trial
copd
random
placebocontrol
phase
iib
trial
three
month
treatment
improv
neither
lung
function
sign
symptom
associ
copd
patient
histori
budesonideformoterol
therapi
anoth
clinic
trial
copd
patient
dose
mg
twice
day
reduc
inflamm
lung
damag
appli
combin
tiotropium
addit
synthet
proteas
inhibitor
plantderiv
proteas
inhibitor
evalu
bauhinia
bauhinioid
l
plant
caesalpinioidea
subfamili
shown
secret
mani
proteas
inhibitor
among
bauhinia
bauhinioid
kallikrein
proteinas
inhibitor
rbbki
bauhinia
bauhinioid
scruzipain
inhibitor
bbci
found
effect
amelior
elastaseinduc
emphysema
figur
model
elastaseinduc
emphysema
model
rbbki
shown
effect
reduc
elastaseinduc
inflamm
extracellular
matrix
remodel
moreov
rbbki
reduc
number
bal
cell
inflammatori
marker
includ
lung
remodel
marker
oxid
stress
marker
eno
ino
marker
respiratori
airway
alveolar
wall
addit
rbbki
diminish
increas
lung
mechan
stress
paramet
respiratori
system
elast
respiratori
system
resist
airway
resist
lung
tissu
elast
lung
tissu
damp
bbci
also
shown
effect
amelior
lung
inflamm
extracellular
lung
remodel
dose
mgkg
recent
potenc
arthropodderiv
serin
proteas
inhibitor
elastaseinduc
emphysema
model
evalu
studi
author
employ
kunitztyp
serin
proteas
inhibitor
test
efficaci
elastaseinduc
emphysema
model
figur
lung
l
found
reduc
recombin
domain
treat
group
addit
instil
reduc
respiratori
mechan
macrophag
neutrophil
lymphocyt
count
bal
fluid
moreov
increas
volum
proport
collagen
elast
fiber
decreas
ne
activ
compar
elastas
treat
group
cathepsin
g
cat
g
one
three
major
serin
proteas
secret
azurophil
granul
neutrophil
addit
antibacteri
activ
cat
g
play
role
innat
immun
chemoattract
extracellular
matrix
degrad
cat
g
found
protect
streptococcu
pneumoniaeinduc
lung
damag
contrast
genet
knockdown
cat
g
also
found
protect
lung
tissu
destruct
longterm
exposur
cigarett
smoke
moreov
increas
express
cat
g
lead
alveolar
wall
destruct
abnorm
secret
mucu
airway
serou
cell
copd
patient
garavilla
et
al
describ
cat
g
inhibitori
activ
lipopolysaccharid
lp
induc
acut
inflamm
model
figur
upon
aerosol
instil
level
exhal
nitric
oxid
reduc
model
addit
neutrophil
lymphocyt
monocyt
eosinophil
basophil
count
bal
among
treat
group
found
significantli
reduc
compar
control
group
anoth
set
experi
group
treatment
reduc
total
cell
count
bal
treat
anim
howev
reduc
neutrophil
load
smokeinduc
inflamm
model
addit
instil
reduc
level
keratinocytederiv
chemokin
kc
murin
homolog
smokeinduc
acut
inflamm
model
studi
demonstr
efficaci
acut
inflamm
model
howev
indepth
studi
chronic
lung
model
requir
order
establish
potenti
treatment
chronic
lung
inflamm
associ
copd
recent
studi
cracian
et
al
demonstr
potenti
narylacyl
osulfon
aminoglycosid
cat
g
inhibit
vitro
model
aminoglycosid
deriv
neomycin
kanamycin
apramycin
show
signific
inhibit
cat
g
ic
dose
rang
howev
vivo
studi
requir
determin
therapeut
potenti
aminoglycosid
treatment
copd
proteinas
abund
serin
proteas
present
azurophil
granul
neutrophil
mostli
activ
immun
respons
infect
autoantigen
wegen
diseas
addit
possess
antibacteri
activ
host
pathogen
pseudomona
aeruginosa
staphylococcu
aureu
aspergillu
fumigatu
candida
albican
degranulationassoci
neutrophil
inflamm
found
play
major
role
copd
pathophysiolog
also
receiv
attent
regard
potenti
role
inflamm
also
take
part
variou
proinflammatori
respons
activ
concentr
well
activ
found
upregul
exacerb
copd
contrast
level
found
stabl
copd
patient
addit
mice
defici
significantli
protect
lung
tissu
destruct
longterm
cigarett
smoke
exposur
month
studi
suggest
role
copd
pathophysiolog
innat
serin
proteas
inhibitor
primarili
secret
epitheli
cell
found
regul
activ
figur
ppeinduc
emphysema
model
reduc
lung
neutrophil
accumul
within
h
intranas
administr
engin
decreas
induc
proinflammatori
cytokin
lung
cell
addit
engin
neresist
variant
ggand
qqelafin
show
promin
antiinflammatori
activ
compar
wtelafin
ggelafin
variant
shown
reduc
inflamm
lp
challeng
vitro
acut
vivo
lung
inflamm
model
yet
anoth
studi
elastaseinduc
emphysema
wtelafin
shown
protect
lung
destruct
prevent
neutrophil
alveol
addit
innat
inhibitor
sever
type
synthet
inhibitor
evalu
efficaci
among
kanamycin
deriv
narylacyl
osulfon
aminoglycosid
kancbz
shown
potent
ic
compar
test
deriv
figur
though
larg
number
studi
shown
antiinflammatori
properti
elafin
clinic
evalu
inhibitor
copd
therefor
clinic
trial
elafin
function
variant
may
interest
futur
treatment
option
copd
dpp
iv
commonli
known
cluster
differenti
cell
surfac
serin
proteas
primarili
cleav
xprolin
xalanin
dipeptid
nterminu
polypeptid
dpp
iv
express
type
ii
transmembran
protein
solubl
form
pertain
ubiquit
natur
also
found
respiratori
tract
lung
parenchyma
type
ii
cell
interstitium
alveolar
macrophag
mononuclear
lymphoid
cell
decreas
serum
level
dpp
iv
found
associ
copd
pathogenesi
independ
age
smoke
histori
importantli
elev
level
dpp
iv
also
associ
acut
exacerb
copd
patient
interestingli
lung
tissu
smoker
endstag
copd
patient
demonstr
higher
express
dpp
iv
nonsmok
tissu
moreov
immunostain
studi
airway
epithelia
pleural
mesothelia
alveolar
macrophag
copd
patient
shown
enhanc
express
dpp
iv
owe
neutrophil
chemorepel
natur
dpp
iv
may
serv
augment
therapi
copd
sever
line
evid
shown
solubl
recombin
dpp
iv
may
import
antiinflammatori
effect
herlihi
et
al
show
recombin
human
dppiv
treatment
reduc
neutrophil
infiltr
type
ii
collageninduc
lung
inflamm
model
addit
dpp
iv
also
found
regul
cxc
motif
chemokin
primarili
activ
inflammatori
cascad
stimul
inflammatori
stimuli
lp
releas
dpp
iv
cell
membran
circul
may
import
copd
pathogenesi
mmp
found
associ
releas
dpp
iv
cell
membran
elev
level
number
mmp
also
found
associ
copd
may
repres
mechan
explain
elev
level
dpp
iv
copd
tryptas
tetramer
serin
proteas
secret
mast
cell
abund
form
serin
proteas
secret
mast
cell
anaphylact
shock
two
type
tryptas
name
addit
activ
role
allerg
reaction
tryptas
also
found
associ
smokingrel
chronic
lung
diseas
increas
tryptas
level
found
bal
smoker
sever
studi
shown
aposit
correl
peripher
airway
tryptas
posit
cell
lung
function
fev
vc
patient
copd
indic
possibl
role
tryptas
diseas
contrast
tryptas
level
found
lower
subepitheli
layer
central
airway
copd
patient
found
correl
lung
function
addit
high
cell
count
level
tryptas
activ
found
elev
time
patient
sever
copd
compar
mild
copd
patient
although
number
tryptas
inhibitor
lactoferrin
apc
mol
nafamostat
mesil
use
studi
underli
signal
mechan
allerg
induc
airway
diseas
model
studi
pertain
copd
pathophysiolog
yet
carri
figur
thu
preclin
studi
evalu
tryptas
inhibitor
copd
model
mayb
use
delin
role
proteas
copd
chymas
serin
proteas
secret
mast
cell
possess
cathepsin
glike
specif
primari
function
chymas
convers
angiotensini
angiotensinii
excess
leakag
chymas
due
higher
mast
cell
degranul
differ
stimul
lead
cellular
matrix
degrad
activ
signal
convers
activ
mmp
zymogen
form
activ
sever
interleukin
etc
endothelin
basic
two
type
chymas
chymas
present
human
wherea
rodent
possess
addit
addit
role
vascular
diseas
chymas
also
found
associ
lung
diseas
pulmonari
fibrosi
pulmonari
arteri
hypertens
pah
asthma
copd
sever
investig
shown
higher
number
chymaseposit
cell
lung
specimen
copd
patient
specif
number
chymaseposit
cell
found
higher
peripher
airway
cell
compar
central
airway
addit
number
chymaseposit
cell
found
posit
correl
fev
predict
among
copd
patient
moreov
chymas
shown
stimul
mucin
product
human
bronchial
epitheli
cell
therefor
inhibit
chymas
may
interest
copd
treatment
mani
investig
shown
inhibit
chymas
profound
effect
vascular
remodel
pah
atherosclerosi
chymas
inhibitor
like
bay
mani
other
test
pf
atherosclerosi
inflamm
figur
studi
relat
effect
copd
limit
de
garavilla
et
al
provid
first
evid
antiinflammatori
effect
chymas
inhibitor
lpsinduc
airway
inflamm
inhibitor
shown
reduc
inflammatori
mediat
within
h
lp
instil
howev
low
oral
bioavail
low
plasma
halflif
rat
aerosol
administr
postul
effect
way
treat
airway
inflamm
anoth
studi
exhibit
antiinflammatori
properti
smokeinduc
airway
inflamm
model
therefor
use
studi
antiinflammatori
effect
chymas
inhibitor
copd
model
dissect
underli
mechan
may
provid
altern
therapeut
target
copd
treatment
near
futur
mmp
zincand
calciumdepend
endopeptidas
respons
extracellular
matrix
remodel
mmp
believ
involv
variou
patholog
condit
includ
inflamm
basi
substrat
specif
mmp
classifi
collagenas
gelatinas
stromelysin
elastas
membranebound
proteinas
addit
transcript
activ
posttranscript
modif
function
activ
mmp
also
found
regul
timp
sever
investig
vitro
vivo
studi
valid
role
mmp
emphysema
pathophysiolog
thu
mani
studi
undertaken
studi
effect
specif
broadspectrum
mmp
inhibitor
emphysema
treatment
among
first
random
doubleblind
studi
undertaken
salmen
et
al
test
efficaci
broad
spectrum
mmp
inhibitor
cigarett
smokeinduc
emphysema
model
guinea
pig
figur
reduc
level
within
month
smoke
exposur
moreov
reduc
alveolar
size
destruct
lung
parenchyma
compar
smoketr
guinea
pig
anoth
set
experi
pemberton
et
al
test
efficaci
inhal
mmp
inhibitor
ilomastat
chronic
smokeexpos
mous
model
figur
ilomastat
reduc
lavag
neutrophil
macrophag
count
time
point
addit
also
reduc
airspac
size
compar
smokeexpos
anim
alon
et
al
synthes
substitut
carboxyl
acid
bay
select
inhibitor
test
efficaci
ppeinduc
emphysema
model
figur
inhibitor
reduc
elastaseinduc
increas
lung
wet
weight
morphometr
analysi
also
show
protect
alveolar
septal
wall
elast
fibr
proteolyt
cleavag
moreov
histolog
data
show
also
protect
lung
hemorrhag
induc
cigarett
smoke
exposur
hand
dual
inhibitor
protect
mice
increas
small
airway
thick
increas
total
lung
capac
residu
volum
vital
capac
smokeexpos
guinea
pig
figur
howev
clinic
random
doubleblind
placebocontrol
studi
select
inhibitor
yield
signific
effect
reduc
symptom
associ
moder
sever
copd
show
protect
alveolar
septal
wall
elast
fibr
proteolyt
cleavag
moreov
histolog
data
show
also
protect
lung
hemorrhag
induc
cigarett
smoke
exposur
hand
dual
inhibitor
protect
mice
increas
small
airway
thick
increas
total
lung
capac
residu
volum
vital
capac
smokeexpos
guinea
pig
figur
howev
clinic
random
doubleblind
placebocontrol
studi
select
inhibitor
yield
signific
effect
reduc
symptom
associ
moder
sever
copd
simvastatin
lipidlow
medic
found
effect
reduc
emphysemat
chang
murin
model
figur
simvastatin
reduc
chang
lm
lung
lung
destruct
significantli
smoketr
mice
addit
simvastatin
reduc
activ
model
clinic
studi
salmeterolfluticason
significantli
reduc
level
sputum
sampl
treat
copd
patient
studi
indic
import
mmp
inhibit
reduc
emphysema
rodent
model
copd
howev
clinic
studi
perform
look
directli
mmp
inhibit
due
offtarget
effect
inhibitor
therefor
develop
refin
specif
mmp
inhibitor
necessari
futur
develop
treatment
copd
although
proteas
antiproteas
imbal
theori
consid
import
mechan
underli
emphysema
develop
mechan
may
explain
patholog
chang
associ
develop
emphysema
vascular
theori
envisag
chronic
loss
epithelium
endothelium
cell
lung
due
alter
program
cell
death
aoshiba
et
al
show
singl
intratrach
inject
activ
mous
lung
could
induc
emphysemat
chang
result
valid
yokohori
et
al
clinic
studi
patient
emphysema
show
percentag
alveolar
wall
cell
undergo
apoptosi
total
number
alveolar
wall
cell
undergo
prolifer
higher
emphysema
patient
compar
healthi
smoker
nonsmok
emphysemat
lung
exhibit
sign
apoptosi
dna
fragment
presenc
activ
bad
bax
fragment
poli
adpribos
polymeras
lung
homogen
increas
apoptosi
mediat
varieti
inflammatori
mediat
includ
receptor
receptor
receptor
inflammasom
simvastatin
lipidlow
medic
found
effect
reduc
emphysemat
chang
murin
model
figur
simvastatin
reduc
chang
l
lung
lung
destruct
significantli
smoketr
mice
addit
simvastatin
reduc
activ
model
clinic
studi
salmeterolfluticason
significantli
reduc
level
sputum
sampl
treat
copd
patient
studi
indic
import
mmp
inhibit
reduc
emphysema
rodent
model
copd
howev
clinic
studi
perform
look
directli
mmp
inhibit
due
offtarget
effect
inhibitor
therefor
develop
refin
specif
mmp
inhibitor
necessari
futur
develop
treatment
copd
although
proteas
antiproteas
imbal
theori
consid
import
mechan
underli
emphysema
develop
mechan
may
explain
patholog
chang
associ
develop
emphysema
vascular
theori
envisag
chronic
loss
epithelium
endothelium
cell
lung
due
alter
program
cell
death
aoshiba
et
al
show
singl
intratrach
inject
activ
mous
lung
could
induc
emphysemat
chang
result
valid
yokohori
et
al
clinic
studi
patient
emphysema
show
percentag
alveolar
wall
cell
undergo
apoptosi
total
number
alveolar
wall
cell
undergo
prolifer
higher
emphysema
patient
compar
healthi
smoker
nonsmok
emphysemat
lung
exhibit
sign
apoptosi
dna
fragment
presenc
activ
bad
bax
fragment
poli
adpribos
polymeras
lung
homogen
increas
apoptosi
mediat
varieti
inflammatori
mediat
includ
receptor
receptor
receptor
inflammasom
lcarbocystein
wellknown
mucolyt
agent
shown
inhibit
hydrogen
peroxidemedi
activ
akt
phosphoryl
airway
epitheli
cell
moreov
carbocystein
also
reduc
airspac
enlarg
alveolar
destruct
rat
lung
expos
cigarett
smoke
lower
mrna
express
lung
parenchyma
model
figur
administr
bosentan
antagonist
day
reduc
smokeinduc
increas
l
destruct
index
lung
tissu
figur
addit
also
lower
distribut
posit
cell
well
mrna
express
lung
tissu
intraperiton
inject
hydrogen
sulfid
h
donor
sodium
hydrosulfid
nah
smokeinduc
emphysema
model
inhibit
smokeinduc
oxid
stress
activ
emphysema
mous
lung
figur
moreov
attenu
level
neutrophil
monocyt
count
decreas
smokeinduc
bronchial
wall
thick
indepth
vitro
studi
resveratrol
show
protect
bronchial
epitheli
cell
smokemedi
apoptosi
attenu
express
figur
studi
provid
evid
target
caspasemedi
apoptot
pathway
order
amelior
emphysema
develop
howev
basic
understand
underli
mechan
behind
role
apoptosi
emphysema
pathogenesi
still
infanc
work
need
done
translat
find
clinic
lcarbocystein
wellknown
mucolyt
agent
shown
inhibit
hydrogen
peroxidemedi
activ
akt
phosphoryl
airway
epitheli
cell
moreov
carbocystein
also
reduc
airspac
enlarg
alveolar
destruct
rat
lung
expos
cigarett
smoke
lower
mrna
express
lung
parenchyma
model
figur
administr
bosentan
antagonist
day
reduc
smokeinduc
increas
lm
destruct
index
lung
tissu
figur
addit
also
lower
distribut
posit
cell
well
mrna
express
lung
tissu
intraperiton
inject
hydrogen
sulfid
donor
sodium
hydrosulfid
nah
smokeinduc
emphysema
model
inhibit
smokeinduc
oxid
stress
activ
emphysema
mous
lung
figur
moreov
attenu
level
neutrophil
monocyt
count
decreas
smokeinduc
bronchial
wall
thick
indepth
vitro
studi
resveratrol
show
protect
bronchial
epitheli
cell
smokemedi
apoptosi
attenu
express
figur
studi
provid
evid
target
caspasemedi
apoptot
pathway
order
amelior
emphysema
develop
howev
basic
understand
underli
mechan
behind
role
apoptosi
emphysema
pathogenesi
still
infanc
work
need
done
translat
find
clinic
cathepsin
cat
elastolyt
cystein
proteas
intracellular
extracellular
activ
includ
tissu
remodel
recent
studi
shown
increas
level
serum
cat
copd
patient
invers
correl
sever
airway
limit
zheng
et
al
show
potent
stimul
cat
select
inhibit
cat
attenu
induc
dna
damag
emphysema
apoptosi
murin
model
increas
number
lymphocyt
peripher
airway
found
associ
copd
addit
cell
count
bronchial
biopsi
also
found
invers
correl
lung
function
chronic
bronchiti
cb
patient
indepth
studi
reveal
crucial
product
lymphocyt
link
alveolar
enlarg
neutrophil
inflamm
enhanc
complic
underli
emphysema
concomit
induct
activ
variou
cathepsin
mmp
select
inhibit
genet
knockdown
studi
cat
illustr
underli
mechan
behind
induc
emphysema
pathophysiolog
interestingli
secretori
leukocyt
proteas
inhibitor
slpi
predominantli
secret
airway
mucos
surfac
inflamm
decreas
induc
cat
express
geraghti
et
al
show
slpi
inhibit
induc
degrad
subsequ
reduc
cat
express
macrophag
figur
although
evid
cat
may
play
role
copd
pathophysiolog
clinic
trial
direct
toward
proteas
conduct
far
moreov
studi
copd
genet
model
provid
valid
use
anticat
therapi
copd
treatment
cathepsin
cat
elastolyt
cystein
proteas
intracellular
extracellular
activ
includ
tissu
remodel
recent
studi
shown
increas
level
serum
cat
copd
patient
invers
correl
sever
airway
limit
zheng
et
al
show
potent
stimul
cat
select
inhibit
cat
attenu
induc
dna
damag
emphysema
apoptosi
murin
model
increas
number
lymphocyt
peripher
airway
found
associ
copd
addit
cell
count
bronchial
biopsi
also
found
invers
correl
lung
function
fev
chronic
bronchiti
cb
patient
indepth
studi
reveal
crucial
product
lymphocyt
link
alveolar
enlarg
neutrophil
inflamm
enhanc
complic
underli
emphysema
concomit
induct
activ
variou
cathepsin
mmp
select
inhibit
genet
knockdown
studi
cat
illustr
underli
mechan
behind
induc
emphysema
pathophysiolog
interestingli
secretori
leukocyt
proteas
inhibitor
slpi
predominantli
secret
airway
mucos
surfac
inflamm
decreas
induc
cat
express
geraghti
et
al
show
slpi
inhibit
induc
degrad
subsequ
reduc
cat
express
macrophag
figur
although
evid
cat
may
play
role
copd
pathophysiolog
clinic
trial
direct
toward
proteas
conduct
far
moreov
studi
copd
genet
model
provid
valid
use
anticat
therapi
copd
treatment
cathepsin
k
cat
k
lysosom
cystein
proteas
found
secret
lung
epitheli
cell
although
role
cat
k
well
known
lung
fibrosi
littl
known
potenti
role
copd
one
studi
demonstr
increas
express
cat
k
lung
homogen
copd
patient
addit
show
chronic
smoke
exposur
significantli
increas
cat
k
express
alveolar
macrophag
cathepsin
cat
aspartyl
endopeptidas
primarili
involv
degrad
protein
lysosom
compart
addit
play
import
role
antigen
process
cell
prolifer
activ
variou
bioactiv
protein
precursor
moreov
cat
also
found
associ
emphysema
similar
activ
mechan
describ
earlier
play
import
role
induct
activ
cat
moreov
increas
express
cat
local
primarili
macrophag
observ
smokeexpos
murin
model
howev
scientif
knowledg
area
cat
mediat
emphysema
pathogenesi
limit
date
cathepsin
e
cat
e
major
intracellular
nonlysosom
aspartyl
proteas
play
import
role
antigen
process
cat
e
found
mainli
associ
differ
type
cancer
elev
express
cat
e
associ
airflow
limit
copd
patient
found
invers
correl
fev
predict
copd
patient
upon
deciph
underli
mechan
behind
increas
express
cat
e
copd
reveal
mediat
increas
express
mitochondri
fission
protein
dynaminrel
protein
activ
caspasedepend
apoptosi
pathway
lead
parenchym
destruct
smokeexpos
murin
model
although
limit
inform
avail
link
cat
e
express
copd
pathogenesi
indepth
mechanist
studi
requir
order
understand
basic
physiolog
behind
activ
copd
dysregul
proteas
activ
result
upregul
proinflammatori
mediat
increas
recruit
inflammatori
cell
lung
inactiv
import
innat
antimicrobi
protein
result
sustain
inflamm
destruct
lung
tissu
one
way
treat
proteasemedi
event
copd
proteas
inhibitor
therapi
howev
translat
promis
proteas
inhibitor
relev
vivo
model
clinic
disappoint
thu
far
mani
clinic
trial
focus
shortterm
benefit
proteas
inhibitor
treatment
longerterm
clinic
trial
may
requir
order
confid
assess
impact
inhibitor
therapi
addit
due
presenc
multipl
proteas
activ
copd
lung
may
import
identifi
definit
whether
key
proteas
proteas
central
direct
tissu
destruct
activ
proteas
diseas
lung
circumst
neutralis
one
proteas
specif
proteas
inhibitor
may
lessen
overal
proteas
burden
copd
without
need
multipl
inhibitor
author
wish
acknowledg
fund
support
medic
research
council
ct
sw
medic
research
council
confid
concept
scheme
ct
sw
author
declar
conflict
interest
